Validation of a flow cytometric acridine orange micronuclei methodology in rats.

Our laboratory has previously reported a flow cytometric acridine orange method for detection of micronucleus (MN) in the rat using cyclophosphamide as a test compound. To replace the manual method of scoring and satisfy Good Laboratory Practice (GLP) requirements, an extensive validation of the flow method was required. Therefore, manual scoring and flow cytometric determination of MN were compared using vincristine, chlorambucil, methotrexate, and doxorubicin compounds known to induce MN formation with various mechanisms of action. 1,2-Dimethylhydrazine (1,2-DH), a compound with negative or equivocal MN findings also was evaluated. The flow method consistently demonstrated dose- and time-dependent responses for MN production at all concentrations of vincristine, methotrexate, clorambucil, and doxorubicin. In contrast, manual scoring of slides failed to detect an increase in MN at the lowest doses of doxorubicin (1mg/kg) at 24 or 48 h, and methotrexate at 48 h, or any dose of methotrexate (50, 100, or 250 mg/kg) at 24h. Additionally, a dose-response for methotrexate at 48 h, and chlorambucil at 24 h were missed using manual scoring. For 1,2-DH, the flow method showed a low level (< 1.4-fold) increase in MN at all doses and times. In contrast, the manual method showed five-seven-fold increases at 24 h, but a < two-fold increase at 48 h in the highest dose only. These data may suggest that the flow method has a greater sensitivity and possibly accuracy than manual scoring. Significant decreases in polychromatic erythrocytes (PCE) were seen using both methods at approximately the same dose for all compounds. However, absolute flow cytometric PCE values were consistently higher than manual. Additional cytotoxicity parameters obtained by the flow method allowed a more complete assessment of cytotoxicity than PCE alone. Furthermore, data reported here combined with improved throughput, shortened data turnaround and reporting times, and possibly better precision due to evaluation of much larger numbers of cells clearly demonstrate the usefulness of flow cytometry method in the routine micronucleus evaluation.

[1]  J. T. Macgregor,et al.  Strategies and testing methods for identifying mutagenic risks. , 2000, Mutation research.

[2]  R R Tice,et al.  In vivo rodent erythrocyte micronucleus assay. , 1994, Mutation research.

[3]  W. R. Bruce,et al.  Comparison of the effects of 1,2-dimethylhydrazine and cyclophosphamide on micronucleus incidence in bone marrow and colon. , 1983, Mutation research.

[4]  G. Choudhary,et al.  Human health perspective on environmental exposure to hydrazines: a review. , 1998, Chemosphere.

[5]  Y. Ikeda,et al.  Reticulocyte maturity as an indicator for estimating qualitative abnormality of erythropoiesis. , 1994, Journal of clinical pathology.

[6]  G Aubel-Sadron,et al.  Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. , 1984, Biochimie.

[7]  L. Abramsson-Zetterberg,et al.  The micronucleus test in rat erythrocytes from bone marrow, spleen and peripheral blood: the response to low doses of ionizing radiation, cyclophosphamide and vincristine determined by flow cytometry. , 1999, Mutation research.

[8]  G. Krishna,et al.  Practical aspects of mutagenicity testing strategy: an industrial perspective. , 2000, Mutation research.

[9]  M. Weinblatt,et al.  Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity , 1991, Current opinion in rheumatology.

[10]  J. T. Macgregor,et al.  The induction of micronuclei as a measure of genotoxicity. A report of the U.S. Environmental Protection Agency Gene-Tox Program. , 1983, Mutation research.

[11]  N. Lawrence,et al.  Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle , 1998, Medicinal research reviews.

[12]  F. Lacombe,et al.  High fluorescence reticulocytes are an indicator of bone marrow recovery after chemotherapy , 1995, European journal of haematology.

[13]  E Mirkova,et al.  Species-specific response to the rodent carcinogens 1,2-dimethylhydrazine and 1,2-dibromo-3-chloropropane in rodent bone-marrow micronucleus assays. , 1988, Mutagenesis.

[14]  S. Dertinger,et al.  Malaria-infected erythrocytes serve as biological standards to ensure reliable and consistent scoring of micronucleated erythrocytes by flow cytometry. , 2000, Mutation research.

[15]  G. Krishna,et al.  Principles and practices of integrating genotoxicity evaluation into routine toxicology studies: A pharmaceutical industry perspective , 1998, Environmental and molecular mutagenesis.

[16]  W Schmid,et al.  The micronucleus test. , 1975, Mutation research.

[17]  S. Rodenhuis,et al.  The clinical pharmacology of alkylating agents in high-dose chemotherapy. , 2000, Anti-cancer drugs.

[18]  D. Niethammer,et al.  Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). , 1998, International journal of molecular medicine.

[19]  J. T. Macgregor,et al.  In vivo rodent erythrocyte micronucleus assay. II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring , 2000, Environmental and molecular mutagenesis.

[20]  M C Cimino,et al.  The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency Gene-Tox Program. , 1990, Mutation research.

[21]  G. Krishna,et al.  Use of acridine orange in: flow cytometric evaluation of erythropoietic cytotoxicity. , 1998, Mutation research.

[22]  M. Hayashi,et al.  In vivo rodent micronucleus assay: protocol, conduct and data interpretation. , 2000, Mutation research.

[23]  B. Margolin,et al.  Guidelines for the conduct of micronucleus assays in mammalian bone marrow erythrocytes. , 1987, Mutation research.